29-Jan-2015 By Fiona BARRY
Google and Biogen Idec are teaming up to crack multiple sclerosis, the latest crossover between pharma and the wearables world.
26-Aug-2014 By Gareth Macdonald
EMD Millipore has been contracted to supply raw materials to the Samsung Biologics plant where ingredients for BM-S’ anticancer monoclonal antibody Yervoy (ipilimumab) are made.
28-May-2014 By Zachary Brennan
As the number of drug approvals declined between 2012 and 2013 by more than 30%, the value of new therapeutic agent approvals seems to indicate a stronger year than initially thought.
24-Apr-2014 By Dan Stanton
Biogen Idec’s five-year deal is the latest example of biopharma embracing the strategic partnership model, but the choice of Quintiles is somewhat of a surprise, according to ISI analyst Ross Muken.
10-Apr-2014 By Dan Stanton
Much of the $91bn (€66bn) raised in biotech capital over the last twelve months will end up in the hands of the CRO industry, according to a survey from analyst firm Jeffries.
18-Oct-2012 By Gareth Macdonald
Reports suggest that Samsung Biologics has halted a trial of a biosimilar version of Roche and Biogen Idec's Rituxan (rituximab).
03-Sep-2012 By Natalie Morrison
in-PharmaTechnologist.com presents its weekly round-up of pharmaceutical career climbers, including news from Eli Lilly, Hovione and Galectin.
14-Jun-2012 By Nick Taylor
Biogen Idec expects the market for injectable MS drugs to shrink as patients choose more convenient delivery forms.
News from Sirona, Hospira, and Biogen Idec – People on the move
31-Jan-2012 By Natalie Morrison
in-PharmaTechnologist presents its weekly round-up of the latest changes on the pharmaceutical career ladder, including news from Sirona, Hospira, and Biogen Idec.
22-Dec-2011 By Gareth Macdonald
Amgen has partnered with non-branded drugmaker Watson to develop biosimilar cancer drugs in a deal that goes some way towards protecting its own portfolio from generic competition.
Samsung and Quintiles' biosimilars JV teams with Biogen Idec
06-Dec-2011 By Gareth Macdonald
Samsung will set up a $300m biosimilars development JV with Massachusetts, US-based Biogen Idec, building on the partnership it forged with CRO Quintiles earlier this year.
News from Genzyme, Catalent and Futura – People on the move
17-Nov-2011 By Natalie Morrison
Outsourcing-Pharma presents its weekly round-up of the latest happenings in the world of pharmaceutical employment, including news from Genzyme, Catalent and Futura.
News from Spectrum, ProtAffin AG, Biogen Idec, and Prosonix – People on the move
03-Oct-2011 By Natalie Morrison
Outsourcing-Pharma presents its round-up of the latest movements within the pharmaceutical industry, including news from Spectrum, ProtAffin AG, Biogen Idec, and Prosonix.
A new CEO at Patheon and appointments at Aesica – People on the move
09-Feb-2011 By Nick Taylor
Outsourcing-Pharma presents its latest round up of movements in the pharma outsourcing sector, including a new CEO at Patheon and appointments at Aesica.
Biogen Idec terminates lixivaptan accord narrowing therapeutic focus
16-Nov-2010 By Gareth MacDonald
Biogen Idec has started shedding development programmes to stay in line with the restructuring plan and job cuts it announced earlier this month.
NexACT enables rectal delivery of biologics, say Apricus Bio
15-Sep-2010 By Alexandria Pešić
Apricus Biosciences, formerly NexMed, announce preclinical data shows NexACT technology enables rectal delivery of biologics, including human antibodies.
Elan mulls hiving-off drug delivery business again
20-Apr-2010 By Gareth Macdonald
Irish drugmaker Elan has once again raised the possibility of selling its delivery business, Elan Drug Technologies (EDT).
A reshuffle at PhRMA and manoeuvring of directors at OSI Pharmaceuticals and Biogen Idec – People on the move
24-Mar-2010 By Nick Taylor
in-PharmaTechnologist presents its latest round up of movements in the pharma sector, including a reshuffle at PhRMA and manoeuvring of directors at OSI Pharmaceuticals and Biogen Idec.
Genzyme strengthening its quality team and appointments at ISPE and Biogen Idec – People on the move
12-Jan-2010 By Nick Taylor
in-PharmaTechnologist presents its latest round up of movements in the pharma sector, including Genzyme strengthening its quality team and appointments at ISPE and Biogen Idec.
The retirement of Biogen Idec’s CEO and appointments at Dishman and Noven – People on the move
06-Jan-2010 By Nick Taylor
in-PharmaTechnologist presents its latest round up of movements in the pharma sector, including the retirement of Biogen Idec’s CEO and appointments at Dishman and Noven.
FDA approves high titre manufacture of Tysabri
20-Apr-2009 By Nick Taylor
The FDA has approved Biogen Idec to manufacture Tysabri using a high titre process but the product’s sales have been “negatively impacted” by the cases of patients developing PML.
Elan cuts staff and offices as Tysabri wavers
15-Dec-2008 By Phil Taylor
Irish drugmaker Elan, which recently dropped plans to sell its Elan Drug Technologies operation, has announced job cuts and the closure of offices in a bid to save cash.
Specialists turn to R&D in tough economic times
02-Dec-2008 By Gareth Macdonald
As more and more delivery firms set their sights on the specialty pharma sector, existing specialty players are increasingly abandoning established licensing strategies in favour of developing drugs in-house to compete.
Enzon may sell Indy plant alongside specialty pharma
12-Aug-2008 By Phil Taylor
Pharmaceutical company Enzon may hive off its entire specialty drugs division, including a manufacturing facility in Indianapolis, US, in the face of pressure from shareholder Carl Icahn.
Biotech acquisitions scale new heights
21-May-2008 By Nick Taylor
Big pharma's lust for biotech's pipelines appears to be continuing
unabated with a record $27bn-worth of acquisitions and licensing
deals being made last year.
Biogen Idec shares nosedive after withdrawing 'for sale' sign
13-Dec-2007 By Mike Nagle
Like countless pets after every Christmas, it seems that nobody
wanted Biogen Idec after all; the firm has announced it will remain
independent after it 'did not receive any definitive offers to
purchase the company'.
Billionaire 'raider' circles as Biogen put up for sale
15-Oct-2007 By Mike Nagle
Biogen Idec has announced it is seeking a buyer for the company and
has already received several expressions of interest - including a
reputed $23bn (€16.2bn) bid from billionaire corporate raider Carl
Biogen bags two discovery partnerships
25-Sep-2007 By Emilie Reymond
Biogen Idec has bagged two new partnerships in the past week which
will see it involved in the search for new drugs for central
nervous system (CNS) and inflammatory ailments.
Biogen dips toe in Indian waters
12-Sep-2007 By Emilie Reymond
US-based biotech firm Biogen Idec has decided to enter the booming
Indian market and establish its presence in the country.
Billionaire to get bigger Biogen stake?
28-Aug-2007 By Emilie Reymond
Investment mogul Carl Icahn could get ready to buy further shares
of biotech company Biogen Idec after getting the green light from
the competition regulators.
Biogen Idec aiming for biologic Alzheimer's drug
22-Aug-2007 By Mike Nagle
A team of scientists at Biogen Idec have unveiled preclinical data
for a potential protein therapeutic to treat Alzheimer's, a disease
normally only attacked using small molecules due to delivery
MS drugs boost Biogen Q2 results
25-Jul-2007 By Emilie Reymond
Biogen Idec has announced healthy financial results for the second
quarter of the year, boosted by high sales of its three leading
Serono relies on Rebif to boost 3Q
25-Oct-2005 By Wai Lang Chu
Serono has announced a mixed third quarter 2005 with product sales
and total revenues weaker than predicted. Its net income beat
market consensus but the company was hit by an $18.3 million (€15.2
million) one-off charge related to...
Biogen Idec cuts staff and sells assets
12-Sep-2005 By Phil Taylor
US biotechnology company Biogen Idec has succumbed to the effects
of having to withdraw its multiple sclerosis drug Tysabri
(natalizumab) earlier this year, cutting 17 per cent of its
workforce and putting manufacturing facilities...
Lonza expands UK biologics facility
Lonza has started a SF 14 million (€9m) expansion of its biologics
manufacturing facility in Slough, UK, in response to what it said
was increasing demand for mammalian cell production for clinical
trials, reports Phil Taylor.
Genentech buys Biogen Idec plant for $408m
US biotechnology company Biogen Idec has said that it plans to sell
a California manufacturing plant built to produce its withdrawn
multiple sclerosis drug Tysabri (natalizumab) to Genentech,
reports Phil Taylor.
Elan break-up under discussion?
Ireland's largest home grown pharmaceutical company, Elan Holdings,
could be split up into two separate units, one focussing on
biotechnology and the other on manufacturing and drug delivery,
according to UK news reports.
New drug extends multiple sclerosis options
The first in a completely new class of drug for multiple sclerosis
has been approved in the US, opening up a new avenue of treatment
for sufferers of the debilitating diseases and potential
blockbuster revenues for developers Elan...
Biotech merger wave gathers up KS Bio
KS Biomedix has confirmed that it is in negotiations that may lead
to a merger and add to the mini-wave of consolidation sweeping over
the UK industry.
IDEC and Biogen forge biggest bio pairing in 2003
The resurgence of merger and acquisition activity in the biotech
industry shows little sign of letting up, with US companies IDEC
Pharmaceuticals and Biogen the latest to step up to the altar